Novartis has announced plans to build a new US radioligand therapy (RLT) manufacturing facility in Winter Park, Florida. The facility represents another milestone in the company’s $23-billion US-based investments first announced in April 2025.

The new 35,000-square-foot facility will come online by 2029 and will strengthen Novartis’ specialized supply chain and manufacturing capabilities across its network of RLT production facilities. The new facility will optimize the delivery of RLT medicines to patients in the Southeast in the US. Over the next five years, Novartis says it will solidify its US RLT manufacturing network, with the new Florida site, the fourth of five existing or planned facilities. The company manufactures RTLs in facilities in Millburn, New Jersey, Indianapolis, Indianapolis, and Carlsbad, California, and a new site is planned in Texas.

With its RTL expansion plan, Novartis says it is on track to produce all of its products requiring advanced technologies in the US, which also includes cell and gene therapies manufactured in Morris Plains, New Jersey, and Durham, North Carolina, and xRNA therapies to be manufactured at a new facility whose location will be announced in the coming months (as reported on November 19, 2025).  

In addition, Novartis announced last November (November 2025), a major expansion plan in North Carolina. Anticipated to open in 2027-2028, the manufacturing hub, encompassing more than 700,000 square feet between the existing campus and new facilities, includes:

• Building a new site in Durham, North Carolina, with the construction of two new facilities dedicated to manufacturing biologics and sterile packaging;
• Building a new site in Morrisville, North Carolina, with one facility for the production of solid dosage tablets and capsules, including packaging; and
• Expanding the scope of its existing Durham, North Carolina, facility with the added capability to support sterile filling of biologics into syringes and vials.

Finally, as part of its US capital expansion, the company plans to establish a $1.1-billion biomedical research hub in San Diego, California, its second global R&D hub in the US. The new complex, expected to open between 2028 and 2029, will serve as the center of the Novartis West Coast Biomedical Research presence, complementing existing hubs in Cambridge, Massachusetts, and Basel, Switzerland.

Source: Novartis